What is the 13F Pro Quality Score for IQV?

13F Pro ranks IQVIA HOLDINGS INC. (IQV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IQV's current score at https://13fpro.ai/research/IQV (free sign-up required for the full ranking).

Which hedge funds own the most IQV stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IQV include BlackRock,, HARRIS ASSOCIATES L P, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/IQV as soon as new 13F filings post.

Where does 13F Pro source IQV data?

All IQVIA HOLDINGS INC. fundamentals and ownership data come directly from SEC EDGAR. IQVIA HOLDINGS INC. files with the SEC under CIK 1478242. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IQV in?

IQVIA HOLDINGS INC. (IQV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IQV research updated on 13F Pro?

IQV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IQVIA HOLDINGS INC.(IQV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1478242 IQV stock profile & AI dashboard →

13F Pro Quality Score

59.7/100

Rank #910 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

47.8/100

Profitability

56.8/100

Balance Sheet

62.6/100

Earnings Quality

35.3/100

Free Cash Flow

68.2/100

Institutional Flow

28.2/100

Revenue Scale

91.2/100

Dilution Risk

46.8/100

IQV Stock Analysis & AI Quality Score

AI stock analysis and institutional research for IQVIA HOLDINGS INC. (IQV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IQV at 59.7/100 on a 32-signal composite quality model, placing it at rank #910 of 2,879 stocks — the top half of the AI-ranked universe. IQV scores in the top quartile across revenue scale (91.2). Areas of concern include institutional flow (28.2) and earnings quality (35.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 46.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), IQVIA HOLDINGS INC. reports quarterly revenue of $4.2B, net income of $274.0M, an operating margin of 12.4%. Top institutional holders of IQV by reported 13-F value include BlackRock,, HARRIS ASSOCIATES L P, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. IQV trades on the NYSE exchange and files with the SEC under CIK 1478242. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IQV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IQVIA HOLDINGS INC. directly from SEC EDGAR. IQVIA HOLDINGS INC.'s 13F Pro composite quality score has ranged between 8 and 67 since 2021, currently 59.7 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about IQVIA HOLDINGS INC.

Quirks, history, and lore behind IQV — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · large-cap · listed on the NYSE · headquartered in North Carolina.
2
The Numbers
Annual revenue of roughly $15 billion, with operations spanning more than 100 countries and a workforce of over 80,000 people.
3
The History
Born from the 2016 merger of two giants — one a contract research organization, the other a healthcare data powerhouse — creating something the industry had never quite seen before.
4
The Secret
Its real superpower is one of the world's largest repositories of anonymous patient-level health data, covering billions of records used to help drug developers run smarter trials.
5
The Lore
It sits squarely in the clinical research outsourcing business, meaning pharma giants pay it to do the painstaking work of running clinical trials so they don't have to.
6
The Giveaway
The name itself is a mashup of IMS Health and Quintiles — two legacy titans of pharma data and contract research — compressed into a ticker that looks like a Scrabble nightmare.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$4.2B

Net Income

Q1 2026

$274.0M

Free Cash Flow

Q1 2026

$491.0M

Operating Margin

Q1 2026

12.4%

ROIC

Q1 2026

2.5%

D/E Ratio

Q1 2026

2.55

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+5.9% YoY

$16.31BFY 2025

FY22 $14.41BFY23 $14.98BFY24 $15.40BFY25 $16.31B

Net Income

-0.9% YoY

$1.36BFY 2025

FY22 $1.09BFY23 $1.36BFY24 $1.37BFY25 $1.36B

Operating Income

-0.9% YoY

$2.18BFY 2025

FY22 $1.80BFY23 $1.98BFY24 $2.20BFY25 $2.18B

EPS (Diluted)

+4.7% YoY

$7.84FY 2025

FY22 $5.72FY23 $7.29FY24 $7.49FY25 $7.84

Total Assets

+11.3% YoY

$29.94BFY 2025

FY22 $25.34BFY23 $26.68BFY24 $26.90BFY25 $29.94B

Total Debt

+12.5% YoY

$15.72BFY 2025

FY22 $12.75BFY23 $13.67BFY24 $13.98BFY25 $15.72B

Op. Cash Flow

-2.3% YoY

$2.65BFY 2025

FY22 $2.26BFY23 $2.15BFY24 $2.72BFY25 $2.65B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2015
Revenue	$16.31B +5.9%	$15.40B +2.8%	$14.98B +4.0%	$14.41B +26.9%	$11.36B +98.0%	$5.74B
Net Income	$1.36B -0.9%	$1.37B +1.1%	$1.36B +24.5%	$1.09B +291.0%	$279.0M -27.9%	$387.0M
Operating Income	$2.18B -0.9%	$2.20B +11.4%	$1.98B +9.9%	$1.80B +146.1%	$731.0M +13.2%	$646.0M
EPS (Diluted)	$7.84 +4.7%	$7.49 +2.7%	$7.29 +27.4%	$5.72 +300.0%	$1.43 -7.1%	$1.54
Total Assets	$29.94B +11.3%	$26.90B +0.8%	$26.68B +5.3%	$25.34B +3.1%	$24.56B +525.7%	$3.93B
Total Debt	$15.72B +12.5%	$13.98B +2.3%	$13.67B +7.3%	$12.75B +1.7%	$12.53B +382.2%	$2.60B
Operating Cash Flow	$2.65B -2.3%	$2.72B +26.4%	$2.15B -4.9%	$2.26B +15.4%	$1.96B	—

AI Insight: IQV Financial Trends

IQV revenue growth accelerating into 2026, but leverage has risen 19% and net income remains volatile despite operational strength.

• Revenue grew 8.8% YoY in Q1 2026 to $4,151M; full-year 2025 revenue $16,481M vs. 2024's $15,668M, reflecting consistent mid-single-digit expansion.

• Operating income margin stable at 12.4% in Q1 2026; Q4 2025 margin hit 14.4%, highest in period, showing operational leverage.

• Total debt climbed to $15,833M in Q1 2026 from $13,258M in Q2 2024, a 19% increase; equity compressed to $6,221M from $6,714M.

⚠ Net income volatility persists: Q1 2026 at $274M despite $514M operating income; earnings conversion inconsistent despite margin improvement.

⚠ Operating cash flow fell 15.9% YoY in Q2 2025 to $443M, the period low; Q1 2026 recovery to $618M suggests timing volatility requiring monitoring.

AI Insight: IQV Ratio Trends

IQVIA's profitability metrics deteriorated sharply in Q1 2026, with operating margin and ROIC both declining to multi-year lows despite stable leverage.

• Operating margin fell to 12.4% in Q1 2026 from 14.4% in Q4 2025, lowest since Q2 2025 (12.6%). Net profit margin compressed to 6.6%.

• ROIC dropped to 9.3% in Q1 2026 from 11.3% in Q4 2025, marking the sharpest quarterly decline in the 9-quarter span.

• Debt-to-equity stabilized at 2.55 in TTM, matching Q1 2026 spot, vs. peak of 2.68 in Q2 2025, showing no deleveraging progress.

⚠ Q1 2026 profitability collapse mirrors Q1 2025 trough (OpMargin 13.0%, ROIC 9.8%), suggesting recurring seasonal or structural headwinds.

⚠ Return on assets at 3.7% in Q1 2026 is lowest since Q1 2025, indicating persistent asset efficiency pressure despite stable D/E.

Get alerted when IQV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IQVIA HOLDINGS INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IQV

BlackRock, Inc.
$2.6B15,027,444 sh
HARRIS ASSOCIATES L P
$2.1B12,183,275 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.9B11,026,983 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.3B7,576,001 sh
STATE STREET CORP
$1.3B7,476,962 sh
Artisan Partners Limited Partnership
$862.7M5,058,865 sh
GEODE CAPITAL MANAGEMENT, LLC
$758.2M4,463,052 sh
Boston Partners
$723.3M4,238,958 sh
ALLIANCEBERNSTEIN L.P.
$648.9M2,878,897 sh
Invesco Ltd.
$556.3M3,261,778 sh

Fund	Value	Shares
BlackRock, Inc.	$2.6B	15,027,444
HARRIS ASSOCIATES L P	$2.1B	12,183,275
VANGUARD CAPITAL MANAGEMENT LLC	$1.9B	11,026,983
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.3B	7,576,001
STATE STREET CORP	$1.3B	7,476,962
Artisan Partners Limited Partnership	$862.7M	5,058,865
GEODE CAPITAL MANAGEMENT, LLC	$758.2M	4,463,052
Boston Partners	$723.3M	4,238,958
ALLIANCEBERNSTEIN L.P.	$648.9M	2,878,897
Invesco Ltd.	$556.3M	3,261,778

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IQV on your watchlist

Track score changes the day IQVIA HOLDINGS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IQV a good stock to buy?

13F Pro's AI-powered analysis of IQVIA HOLDINGS INC. (IQV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IQV are available on the IQV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IQV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IQV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IQVIA HOLDINGS INC.'s investment landscape.